Biogen delays Alzheimer's drug filing plans, shares fall 11%

(Reuters) - Biogen Inc on Wednesday delayed the filing for marketing approval of its experimental Alzheimer's disease drug, saying that it needed more time to prepare the data before submission.Shares of the company fell 11% in morning trading after the company said it would now file the application in the third quarter instead of the early part of the year."We don't want to rush (the filing) and then face challenges," Chief Executive Officer Michel Vounatsos said. "Quality is important and..